HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib von Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T.L., Tu, M.M., Yu, H., Ji, H., Zhou, C., Ren, S., Zhang, J., Bunn, P., Doebele, R.C., Camidge, D.R., Hirsch, F.R.

Volltext

SP 134 Predictive and pharmacodynamic markers of susceptibility for targeting IGF-1R receptor von Hirsch, F.R

Volltext

Consensus for HER2 alterations testing in non-small-cell lung cancer von Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D.H., Wang, Z., Chu, Q., Mack, P.C., Cheng, Y., Duan, J., Fan, Y., Han, B., Hui, Z., Liu, A., Liu, J., Lu, Y., Ma, Z., Shi, M., Shu, Y., Song, Q., Song, X., Song, Y., Wang, C., Wang, X., Wang, Z., Xu, Y., Yao, Y., Zhang, L., Zhao, M., Zhu, B., Zhang, J., Zhou, C., Hirsch, F.R.

Volltext

I.17 ALK Genomic Aberrations in NSCLC and Clinical Implications von Hirsch, F.R.

Volltext

IBS15.02 Determinants of Response to ICI von Hirsch, F.R.

Volltext

Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study von Gadgeel, S., Kowanetz, M., Zou, W., Hirsch, F.R., Kerr, K.M., Gandara, D.R., Barlesi, F., Park, K., McCleland, M., Koeppen, H., Ballinger, M., Sandler, A., Hegde, P.S., Rittmeyer, A.

Volltext

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes von Schmid, P, Kowanetz, M, Koeppen, H, Zou, W, Wistuba, I, Kockx, M, Kadel, E.E, Chaft, J, Rizvi, N.A, Hirsch, F.R, Smith, D, Miley, N, Leveque, V, Shames, D.S, Sandler, A, Mellman, I, Chen, D.S, Hegde, P.S, Gettinger, S

Volltext

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Canc... von Hirsch, F.R, Govindan, R, Zvirbule, Z, Braiteh, F, Rittmeyer, A, Belda Iniesta, C, Isla, D, Cosgriff, T, Boyer, M, Ueda, M, Phan, S, Gandara, D

Volltext

335 mTOR Inhibitor CC-223 Acts in Synergy with Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer Cell Li... von Ekman, S, Wynes, M.W, Chan, D, Hege, K, Xu, S, Hirsch, F.R

Volltext

484 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients von Innocenti, F, Owzar, K, Jiang, C, Crona, D, Etheridge, A, Jassem, J, Rzyman, W, Hirsch, F.R, Dziadziuszko, R, Glubb, D.M

Volltext

Role of biomarkers for early detection of lung cancer and chemoprevention von Hirsch, F.R, Merrick, D.T, Franklin, W.A

Volltext

Targeted Therapy for Lung Cancer and Pancreatic Toxicity: Retrospective Study and Recommendations von Meyer, M.L., Gros, L., Decosterd, N., Tagliamento, M., Planchard, D., Combarel, D., Besse, B., Hirsch, F.R., Aldea, M.

Volltext

OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers von Zhang, X., He, Y., Hirsch, F.R., Zhou, C.

Volltext

163P - OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers von Zhang, X., He, Y., Hirsch, F.R., Zhou, C.

Volltext

Chemoprevention of lung cancer—from biology to clinical reality von Winterhalder, R. C., Hirsch, F. R., Kotantoulas, G. K., Franklin, W. A., Bunn Jr, P. A.

Volltext

P2.02-070 C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer von Tsakonas, G., Hirsch, F.R., Ekman, S.

Volltext

The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC von Hirsch, F.R

Volltext

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus... von Paz-Ares, L., Socinski, M.A., Shahidi, J., Hozak, R.R., Soldatenkova, V., Kurek, R., Varella-Garcia, M., Thatcher, N., Hirsch, F.R.

Volltext

EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed von Nakajima, E., Sugita, M., Morishita, Y., Miyazaki, T., Kanzawa, H., Kawaguchi, Y., Ono, S., Hirsch, F.R., Ikeda, N., Furukawa, K.

Volltext

EP.08F.01 Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) von Tavolacci, S.C., Wang, X.A., Chun, G., Bloom, J., Mendoza, D.P., Tignor, N., Van Vleck, T., Chang, S., Chung, M., Tuminello, S., Wisnivesky, J., Hirsch, F.R., Cotarla, I., Simmons, D., Hsieh, K., Samstein, R.M., Wang, P., Veluswamy, R.

Volltext